The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely through paracrine signaling rather than engraftment and differentiation, a reframing captured in Arnold Caplan’s proposal to rename them “medicinal signaling cells.” What hasn’t matured is the public’s understanding of any of it. [Read more…]